| Basics |
iBio, Inc.
iBio Inc is a biotechnology company. It is engaged in commercializing its proprietary platform technologies, iBioLaunch for vaccines and therapeutic proteins & iBioModulator for vaccine enhancement and developing select product candidates.
|
| IPO Date: |
January 4, 2011 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$13.36M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.08 | 5.63%
|
| Avg Daily Range (30 D): |
$0.05 | 5.87%
|
| Avg Daily Range (90 D): |
$0.18 | 6.34%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.72M |
| Avg Daily Volume (30 D): |
1.29M |
| Avg Daily Volume (90 D): |
.81M |
| Trade Size |
| Avg Trade Size (Sh.): |
521 |
| Avg Trade Size (Sh.) (30 D): |
335 |
| Avg Trade Size (Sh.) (90 D): |
269 |
| Institutional Trades |
| Total Inst.Trades: |
120 |
| Avg Inst. Trade: |
$1.48M |
| Avg Inst. Trade (30 D): |
$1.08M |
| Avg Inst. Trade (90 D): |
$1.08M |
| Avg Inst. Trade Volume: |
.88M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.86M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
2.49M |
|
|
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.31
|
$-.49
|
$-.48
|
|
Diluted EPS
|
$-.32
|
$-.49
|
$-.48
|
|
Revenue
|
$ .38M
|
$ M
|
$ .2M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -20.99M
|
$ -4.86M
|
$ -4.36M
|
|
Operating Income / Loss
|
$ -16.81M
|
$ -4.88M
|
$ -4.42M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -1.25M
|
$ -2.06M
|
$ -4.02M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 29, 2023:
1:20
|
|
Oct 10, 2022:
1:25
|
|
Jun 11, 2018:
1:10
|
|
